Leaked TPP text confirms "TRIPS-plus" provisions
This article was originally published in SRA
Text leaked from the secretive talks on the Trans-Pacific Partnership confirms that US negotiators are pressing for tough intellectual property (IP) provisions that will please the R&D-based industry. Public health campaigners, however, say the provisions go beyond current international requirements and will severely limit access to medicines in many developing countries.
You may also be interested in...
Companies marketing dexamethasone in Europe have been told they can use a CHMP endorsement to request the addition of COVID-19 to their product license.
A “powerful new vision” for the post-Brexit UK regulatory framework was unveiled at a conference organized by the BioIndustry Association and the medicines regulator, the MHRA.
InflaRx and Relief Therapeutics/NeuroRx are investigating potential new treatments for COVID-19-induced pneumonia and for coronavirus-related ARDS.